Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    (a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

    Int J Cancer. 2019, 144(4):777-787. Nutlin-3a purchased from Selleck.

  • Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

    Cancer Lett, 2016, 381(2):370-9. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • C) Control-threated cells show an strong nuclear expression of MDM2 and predominantly cytoplasmic localization of FOXM1. D) After treatment with nutlin-3a, the MDM2 immunoreactivity shifted to the perinuclear space indicating a de novo 952 MDM2 synthesis as result of increased p53 activity. In those cells, FOXM1 expression is lost due to p53 activation.

    Neuroendocrinology, 2018, 107(1):1-23. Nutlin-3a purchased from Selleck.

    Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L3Z2lEPTB;MD62NVI{PyEQvF2= M2e1c3NCVkeHUh?=
H4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNk[yPEDPxE1? MnjDV2FPT0WU
PA-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPjfohKSzVyPUCuPFcxQTZizszN M4PEVHNCVkeHUh?=
NKM-1 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn3SGNKSzVyPUGuNFQ6OzFizszN MkfxV2FPT0WU
NEC8 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDUTWM2OD1zLkKxOVczKM7:TR?= NGex[3NUSU6JRWK=
EoL-1-cell NIX2[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXQUFUzUUN3ME2xMlI3PzBzIN88US=> MkP0V2FPT0WU
K5 NY\IU5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1b2xEUUN3ME2xMlQzODd{IN88US=> NFjjZ2RUSU6JRWK=
QIMR-WIL NFu5VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD1zLk[wPFU1KM7:TR?= M{XlenNCVkeHUh?=
MOLT-16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHsTWM2OD1zLke4OlA1KM7:TR?= NITZcY5USU6JRWK=
CHP-212 NIDPRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZTWM2OD1zLkixN|Y6KM7:TR?= NHL6O3ZUSU6JRWK=
CTB-1 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKwTWM2OD1{LkCyNlQ3KM7:TR?= NF3SeYxUSU6JRWK=
MOLT-4 NUf2OmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTPNHRMUUN3ME2yMlMzQDV|IN88US=> NYrM[4FEW0GQR1XS
A101D MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXFO41KSzVyPUKuN|UxOSEQvF2= NHrWRnBUSU6JRWK=
DOHH-2 NW\PWFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwNEKyO|kh|ryP NYXsdWF2W0GQR1XS
ES4 M1;ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC3fGFKSzVyPUKuOFMyPTVizszN MYrTRW5ITVJ?
SW780 NWfwOmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzoPJBKSzVyPUKuOVA5QDNizszN NYfldplGW0GQR1XS
VA-ES-BJ NYrSfZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m5V2lEPTB;Mj61OFEyKM7:TR?= MnjqV2FPT0WU
RPMI-8866 NFHlUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TV[mlEPTB;Mj61OlIyPCEQvF2= NGHlZ21USU6JRWK=
ML-2 M4Xrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj3V2VnUUN3ME2yMlU3PTd4IN88US=> NY\nV4ROW0GQR1XS
MSTO-211H MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P0UGlEPTB;Mj61O|Q2OSEQvF2= Mn\VV2FPT0WU
JVM-3 M3zucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwNUmzNlQh|ryP NX;1WGI1W0GQR1XS
A3-KAW NXLXOZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3lZ5BKSzVyPUKuOlE5OThizszN M3TCfnNCVkeHUh?=
DK-MG NE[zV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PPRmlEPTB;Mj62NlQ4OSEQvF2= MX\TRW5ITVJ?
LNCaP-Clone-FGC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnzcYhlUUN3ME2yMlY1OzF6IN88US=> M{TkU3NCVkeHUh?=
HT-144 M1TsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD2WmNwUUN3ME2yMlY1PTd5IN88US=> MlHnV2FPT0WU
NB69 M3;KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaT4c5UUN3ME2yMlY2OzN2IN88US=> NWPRTlZZW0GQR1XS
A172 NYKzfYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ETWM2OD1{Lk[3OVg5KM7:TR?= NYjrcZNoW0GQR1XS
RS4-11 NXTwR3pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD1{LkeyOFA4KM7:TR?= NEHrVVZUSU6JRWK=
DU-4475 NVrNWWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37JXWlEPTB;Mj63PVUxOiEQvF2= NYnE[odQW0GQR1XS
SJSA-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwOEK1OVYh|ryP M4j5V3NCVkeHUh?=
BV-173 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDue4tKSzVyPUKuPFQ1OzlizszN NHr4VG1USU6JRWK=
U-2-OS NYn6eGlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP2bIFKSzVyPUKuPVExPyEQvF2= MXvTRW5ITVJ?
CHP-134 NFzvfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwOUO4PFIh|ryP M2HuRXNCVkeHUh?=
D-502MG MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu3WopKSzVyPUKuPVcyPTRizszN NF\CW4ZUSU6JRWK=
KS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX2TWM2OD1|LkCxOlI{KM7:TR?= NHviZ|hUSU6JRWK=
A204 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnOR5hwUUN3ME2zMlA2PTh6IN88US=> NWT2fWJSW0GQR1XS
KGN Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrkTWM2OD1|LkC4OFk3KM7:TR?= MVzTRW5ITVJ?
NCI-H292 M3Oy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrGV5FKSzVyPUOuNVIxOjhizszN NIXxVoRUSU6JRWK=
CAKI-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi1[ZJpUUN3ME2zMlEzPjl2IN88US=> MkDkV2FPT0WU
C2BBe1 NV\KWZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUXmV1UUN3ME2zMlE4ODJ4IN88US=> MYHTRW5ITVJ?
NB10 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vSOGlEPTB;Mz6yNFk3PiEQvF2= MXLTRW5ITVJ?
MHH-NB-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PhVmlEPTB;Mz6yOlgzPyEQvF2= NWrwRWp1W0GQR1XS
NCI-SNU-1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLjeZJKSzVyPUOuNlc5PDNizszN M3jlZ3NCVkeHUh?=
HCT-116 M360b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T6b2lEPTB;Mz6zNFM{PSEQvF2= NVLsTVdTW0GQR1XS
G-401 NXXjbI06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjYTVRKSzVyPUOuN|Y{OjJizszN NYrPPI1TW0GQR1XS
MN-60 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\tVmlEPTB;Mz60OFA6OiEQvF2= NUSzd|RPW0GQR1XS
SW982 NWLSfXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nlSmlEPTB;Mz61NFg1QCEQvF2= MVzTRW5ITVJ?
RKO NG\2fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNwNUO5N|Yh|ryP MlXBV2FPT0WU
D-283MED M2HO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3SWopoUUN3ME2zMlU4QTh4IN88US=> NXLHdHRKW0GQR1XS
LB996-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXyZXR6UUN3ME2zMlYzPTV6IN88US=> NFn0[ZZUSU6JRWK=
A549 NHHYdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKyOVVKSzVyPUOuOlM2PTJizszN NVTzS3FsW0GQR1XS
LB2241-RCC M4HQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCTWM2OD1|Lk[1O|A5KM7:TR?= M1jlV3NCVkeHUh?=
SK-HEP-1 NIXjZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwN{SyPVch|ryP NGPUV2VUSU6JRWK=
G-402 NYLreZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnadmZKSzVyPUOuPFA5OzJizszN MoPaV2FPT0WU
GOTO NUfvZYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjQUldKSzVyPUOuPFQ{OzNizszN NUC0fVRbW0GQR1XS
LOXIMVI NXfLc5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNwOEW2O|Uh|ryP NVftTHlwW0GQR1XS
NH-12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMEG5OVkh|ryP Mk[wV2FPT0WU
CTV-1 NVW4NJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1noXWlEPTB;ND6wO|k4OyEQvF2= Mn;wV2FPT0WU
CP50-MEL-B M3XwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXCfFdKSzVyPUSuNlQ{QTJizszN MVnTRW5ITVJ?
RH-18 M1fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDiTWM2OD12LkK3O|A3KM7:TR?= NGexeHBUSU6JRWK=
NB17 M4HaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;KSJlnUUN3ME20MlMyPzZ6IN88US=> MXPTRW5ITVJ?
A375 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyzVIFKSzVyPUSuN|M2OjRizszN NVnGdpBDW0GQR1XS
IST-MES1 NXHrb4puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwNEG0NVEh|ryP MVrTRW5ITVJ?
MZ2-MEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\aTWM2OD12LkWwNVU2KM7:TR?= MVPTRW5ITVJ?
CAL-54 NX;s[5AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHRTWM2OD12LkWzNFE6KM7:TR?= MW\TRW5ITVJ?
NCI-H28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDGTWM2OD12Lk[yO|E4KM7:TR?= NYnUeFh1W0GQR1XS
D-247MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjMV2JXUUN3ME20Mlc2ODd{IN88US=> MnLqV2FPT0WU
NCI-H460 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjBV3NKSzVyPUSuPVEyOjdizszN M3O1NXNCVkeHUh?=
MCF7 NGLpcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3EN|FbUUN3ME21MlQ1OjR2IN88US=> NUnFNVhYW0GQR1XS
697 M2H6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwNES1OUDPxE1? MkPlV2FPT0WU
ONS-76 NWPZ[mI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBTWM2OD13LkW3NFA6KM7:TR?= NWXadJM4W0GQR1XS
C32 NI\MNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPZS5FKSzVyPUWuOlAxOjlizszN M1n4OnNCVkeHUh?=
OS-RC-2 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XyUmlEPTB;NT63N|g5PyEQvF2= NIS0eWtUSU6JRWK=
MEL-HO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T1VWlEPTB;NT64OVY3PyEQvF2= NY\0SnM1W0GQR1XS
LoVo NEDtVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHn[m5OUUN3ME22MlAyPjJ2IN88US=> NIXXZ5hUSU6JRWK=
AGS Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwMUS4Nlgh|ryP NGDGUWxUSU6JRWK=
GI-ME-N MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jQXWlEPTB;Nj6yNlQzOSEQvF2= M2Hsc3NCVkeHUh?=
H-EMC-SS MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnizTWM2OD14LkO4OkDPxE1? NU\nS3FRW0GQR1XS
RVH-421 M2fFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P4TWlEPTB;Nj60NlQzQCEQvF2= M{DpenNCVkeHUh?=
SW954 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwNUW1O|Ih|ryP MX\TRW5ITVJ?
NB5 M4rLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3yOWhKSzVyPU[uOVYyQDNizszN MUDTRW5ITVJ?
NCI-H2122 NV\2SWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13HSWlEPTB;Nj61PFc6OyEQvF2= M3nNS3NCVkeHUh?=
AM-38 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZwN{W2N|kh|ryP MW\TRW5ITVJ?
KNS-81-FD MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZwN{[0PVQh|ryP MlTYV2FPT0WU
LS-513 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjUTWM2OD14Lke5NFI3KM7:TR?= NFH1W2VUSU6JRWK=
A427 NWSxd4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[wTWdUUUN3ME22Mlg4QDJ7IN88US=> MYXTRW5ITVJ?
WM-115 M{T0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnJWGRKSzVyPU[uPVMzOyEQvF2= MUHTRW5ITVJ?
COLO-829 NFL1R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rCO2lEPTB;Nz6yOFE5QCEQvF2= NILEb|NUSU6JRWK=
NCI-H1650 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTiTWM2OD15LkO5NlI5KM7:TR?= NXrqS|RLW0GQR1XS
NCI-H358 NHvrSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnWU|RKSzVyPUeuOFQ5PzlizszN NWTYUoZMW0GQR1XS
HT-1080 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrxc2w4UUN3ME23MlQ5OjV2IN88US=> NETWXZpUSU6JRWK=
HCC2218 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7pS2FKSzVyPUeuOlI6PyEQvF2= Mo\vV2FPT0WU
NCI-H661 NHPy[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTdwOEewOlkh|ryP M2rl[nNCVkeHUh?=
KM-H2 M1LJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi5[XlKSzVyPUeuPFg3QTRizszN MnTlV2FPT0WU
RPMI-2650 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjRTWM2OD15Lkm0OFE1KM7:TR?= NFHNc5dUSU6JRWK=
NCI-H226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfXeXpKSzVyPUiuNlEyOjJizszN NVjISnVDW0GQR1XS
MKN45 M3PMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;NW5RKUUN3ME24MlI3PjB{IN88US=> M{TyXnNCVkeHUh?=
D-392MG NX\Ic5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfLW5VKSzVyPUiuOVI4OjJizszN NHiwXZJUSU6JRWK=
RCC10RGB M{GzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRThwOE[2PVUh|ryP NHPofmFUSU6JRWK=
CAL-51 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTlwMUCyOVEh|ryP NGPBdHBUSU6JRWK=
COLO-678 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVji[mF6UUN3ME25MlMzQDFzIN88US=> NIn2XIpUSU6JRWK=
SK-MEL-24 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTlwNUW4OVYh|ryP MnvBV2FPT0WU
SK-MEL-30 M2H3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\yO2lEPTB;OT65OFQ4PiEQvF2= MnPEV2FPT0WU
MMAC-SF NGfnblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;oepdKSzVyPUGwMlM6PjFizszN NHPWTGhUSU6JRWK=
NTERA-S-cl-D1 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyLk[1NFgh|ryP MnTvV2FPT0WU
NB12 NH\iWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335TmlEPTB;MUGuOVA{KM7:TR?= NX;EbGhUW0GQR1XS
UACC-257 NYnoPYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rGPWlEPTB;MUGuPFY6PSEQvF2= MULTRW5ITVJ?
LAN-6 NX;DU3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFzLkm5Nlgh|ryP MX;TRW5ITVJ?
SW1573 NW\5dI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPrVopFUUN3ME2xNk4{ODh4IN88US=> MX\TRW5ITVJ?
NMC-G1 NFG0c|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;wTWM2OD1zMj60NVc2KM7:TR?= MUnTRW5ITVJ?
SHP-77 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrTGlEPTB;MUKuOVU4PCEQvF2= MWPTRW5ITVJ?
IGROV-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITQ[HNKSzVyPUGyMlY2PzNizszN MliwV2FPT0WU
22RV1 M2LSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHIcm5{UUN3ME2xNk45ODV7IN88US=> MWfTRW5ITVJ?
SK-MEL-3 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m2[mlEPTB;MUOuN|k4OyEQvF2= NYm0ZW5GW0GQR1XS
NCI-H1563 NF;WPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\tOmh1UUN3ME2xN{41OjB{IN88US=> MkXzV2FPT0WU
IGR-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF2LkCzOFch|ryP MnKwV2FPT0WU
EW-3 NWHiUJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnezTWM2OD1zND6xOlM6KM7:TR?= NUPLO41CW0GQR1XS
JEG-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2yTWM2OD1zND60PVU{KM7:TR?= M4P0W3NCVkeHUh?=
ES3 NGTCeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XGd2lEPTB;MUSuOlU3OiEQvF2= Mmi3V2FPT0WU
MDA-MB-175-VII M4nIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\lepNKSzVyPUG0MlcyOTFizszN NH3Be|dUSU6JRWK=
P30-OHK NYnhZ4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX3TWM2OD1zNT6wOFk3KM7:TR?= NGSzR2JUSU6JRWK=
GP5d NHX4U4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K3dmlEPTB;MUWuNVQ3PiEQvF2= MkDBV2FPT0WU
HMV-II M4PnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTWTWM2OD1zNT6zN|M{KM7:TR?= NF;4OlVUSU6JRWK=
COLO-679 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPUR3lKSzVyPUG1MlUxOSEQvF2= M3LIPHNCVkeHUh?=
JAR M1rFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC0SVZXUUN3ME2xOU44OjB3IN88US=> MortV2FPT0WU
NCI-H1666 NWe5W4xST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1zNT65N|k6KM7:TR?= M3y3VnNCVkeHUh?=
SW48 M1vDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF3Lkm1NVYh|ryP MX;TRW5ITVJ?
NCI-H720 M3X2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF3Lkm5PFkh|ryP NVW4fVB3W0GQR1XS
HT-1197 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJbHdGUUN3ME2xOk4xOzV{IN88US=> NXHhbmp{W0GQR1XS
HL-60 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXnTWM2OD1zNj6wN|g1KM7:TR?= MXnTRW5ITVJ?
BEN M2roO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOyOlNKSzVyPUG2MlU3OzhizszN NXH5c45XW0GQR1XS
HAL-01 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3DTWM2OD1zNj64PVA6KM7:TR?= MYHTRW5ITVJ?
SW900 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD1zNj65NVMzKM7:TR?= MY\TRW5ITVJ?
SBC-1 M4fVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXncXdKSzVyPUG3MlU1OjlizszN NWPuXWVZW0GQR1XS
SH-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF5LkW4OFEh|ryP MkjtV2FPT0WU
UACC-62 M4XnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC5WYNKSzVyPUG3Mlc3OzdizszN NVTvZ3VLW0GQR1XS
BHT-101 M{XqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzTZ3U{UUN3ME2xPU45PzB3IN88US=> NEP0NIRUSU6JRWK=
DB M1vSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJzLkW2OFkh|ryP NF;3V3NUSU6JRWK=
SK-MEL-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTqWlJWUUN3ME2yNU42QDd{IN88US=> MUXTRW5ITVJ?
NCI-H747 M2T1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZc5BKSzVyPUKyMlc{PzlizszN MkO0V2FPT0WU
SK-LU-1 NXXPRpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ|LkO1NlQh|ryP MXzTRW5ITVJ?
KG-1 NGq4OGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ|LkS5OFYh|ryP NVTDZlU4W0GQR1XS
LXF-289 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTiTWM2OD1{Mz63NVQh|ryP NX30[lhQW0GQR1XS
HCC1954 MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPuWolKSzVyPUK0Mlg5PDRizszN NVnlcpgzW0GQR1XS
Ramos-2G6-4C10 M3zyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DtS2lEPTB;Mk[uOFk5OSEQvF2= NVXiUVM{W0GQR1XS
DBTRG-05MG NV7VWZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPwOYJZUUN3ME2yOk43PDh6IN88US=> MW\TRW5ITVJ?
NCI-H2052 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKxbYZKSzVyPUK3MlU3QDRizszN NXi3TVJWW0GQR1XS
RMG-I NHLFSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe0TWM2OD1{OT60NVM6KM7:TR?= MW\TRW5ITVJ?
H9 NEm4VWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LnWGlEPTB;M{GuN|AxQCEQvF2= NIP1bWtUSU6JRWK=
GR-ST NWDwdpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN{LkS0OVMh|ryP Mn32V2FPT0WU
Mo-T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rX[mlEPTB;M{KuOVA1PiEQvF2= MWPTRW5ITVJ?
SW1088 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWwfZlCUUN3ME2zNk46QDBzIN88US=> NHvJbIpUSU6JRWK=
LB2518-MEL MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HjbGlEPTB;M{OuNFc6PyEQvF2= MnjaV2FPT0WU
NCI-H82 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN|LkG2OlEh|ryP M2rIXXNCVkeHUh?=
LAMA-84 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLzOHYzUUN3ME2zOE43ODd|IN88US=> NVfoV4ZMW0GQR1XS
KYSE-450 MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj5PFNJUUN3ME2zOE43Pzd4IN88US=> Mo\mV2FPT0WU
LU-99A NEP2UIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf5bZUxUUN3ME2zOU4xODB5IN88US=> NFXIUJpUSU6JRWK=
BE-13 NVjZNXFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnUSVNFUUN3ME2zOU43PTR3IN88US=> NYe0ZZJTW0GQR1XS
GAK NGHSc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvBTZlKSzVyPUO1MlY6PSEQvF2= NVvld4s{W0GQR1XS
NCI-H1573 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN3Lki4NVgh|ryP MVrTRW5ITVJ?
AsPC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXWRohKSzVyPUO2MlE2OjdizszN M3Lzb3NCVkeHUh?=
HDLM-2 NGXxXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn0cZF{UUN3ME2zOk4{OTZizszN M1\nR3NCVkeHUh?=
NCI-H441 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfSNIZKSzVyPUO3MlA3QTFizszN MkO3V2FPT0WU
CAL-27 NI[4[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPROHl7UUN3ME2zO{44OjNzIN88US=> NYmxb4wxW0GQR1XS
OVCAR-3 NUTvfFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ywfWlEPTB;M{muN|E5OSEQvF2= NXvBSVVnW0GQR1XS
RPMI-8226 NGPPSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PVemlEPTB;M{muOVk5KM7:TR?= NGrUNHhUSU6JRWK=
EFO-21 M1XBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H6UGlEPTB;NECuOVgyPCEQvF2= MonVV2FPT0WU
SNU-C2B MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRzLkWwPFQh|ryP NInaWXhUSU6JRWK=
VM-CUB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHLd4M2UUN3ME20N{45ODN5IN88US=> MUTTRW5ITVJ?
NCI-H2087 NWTVZmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jFcGlEPTB;NEWuNFI{OyEQvF2= NWizR|lRW0GQR1XS
EW-16 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6weIxKSzVyPUS2MlMyOzdizszN NUXybnN2W0GQR1XS
SK-N-AS MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD12Nj63NVY4KM7:TR?= NUjNSldEW0GQR1XS
COR-L105 NEm1TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTKTWM2OD12Nj64PFU4KM7:TR?= NWDRe|ZnW0GQR1XS
DEL Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrrXJRKSzVyPUS4MlA1OjlizszN M2TGNnNCVkeHUh?=
JVM-2 M3O1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jhO2lEPTB;NEiuNFU2QCEQvF2= NYjUOoNZW0GQR1XS
KARPAS-45 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR7LkS1N|gh|ryP M2TuZ3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID